论文部分内容阅读
目的:观察信必可都保(布地奈德-福莫特罗)对稳定期非囊性纤维化支气管扩张患者的临床疗效。方法:将42例稳定期非囊性支扩患者随机分为对照组(20例,常规服用氨茶碱0.1g,tid)、观察组(22例,在常规基础上加用信必可都保吸入剂,160μg/4.5μg,tid),疗程3个月,比较治疗前后两组肺功能指标(FEV1、FVC和PEF)及SGRQ评分。结果:对照组试验前后肺功能、SGRQ评分无显著改变(P>0.05);观察组肺功能无显著改变(P>0.05),SGRQ评分显著降低,差异有统计学意义(P<0.05)。结论:长期使用信必可都保吸入剂对稳定期非囊性纤维化支扩患者的生活质量有明显的改善作用,可有效控制气道炎症,但对改善肺功能无显著效果。
OBJECTIVE: To observe the clinical efficacy of etoposide (budesonide-formoterol) in patients with stable non-cystic fibrosis bronchiectasis. Methods: Forty-two patients with stable non-cystic dehiscence were randomly divided into control group (n = 20, routinely taking aminophylline 0.1g, tid) and observation group (n = 22) Inhalation, 160μg / 4.5μg, tid) for 3 months. The indexes of pulmonary function (FEV1, FVC and PEF) and SGRQ were compared before and after treatment. Results: The lung function and SGRQ score of the control group had no significant change before and after the test (P> 0.05). The lung function of the observation group had no significant change (P> 0.05). The SGRQ score was significantly lower (P <0.05). CONCLUSION: Long-term use of bixiturubicin inhalation can significantly improve the quality of life of patients with stable non-cystic fibrosis and support the airway inflammation, but has no significant effect on improving pulmonary function.